ZURICH (Reuters) – Swiss drugmaker Novartis said on Tuesday that a large British study of its cholesterol-lowering drug Leqvio is now not expected to be completed until 2026, a year later than expected, as COVID-19 infections made participant recruitment difficult.
In January 2020, Novartis struck a deal with the National Health Service to use its data to identify patients at risk of heart disease for whom conventional treatment has been unsuccessful. They are due to get Leqvio, which targets “bad cholesterol” that can cause heart attacks and strokes. (https://reut.rs/3xmxxtf)
(Reporting by John Miller; Editing by Michael Shields)
